Pacira BioSciences (PCRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $36.34, +0.03% vs the prior close of $36.33.
- Volume 960.89K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PCRX ends flat (+0.0%) to $36.34. Closed at $36.34, +0.03% vs the prior close of $36.33. Day range $36.33–$36.39, opened at $36.36.
PCRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PCRX ends flat (+0.0%) to $36.34
- Closed at $36.34, +0.03% vs the prior close of $36.33. Day range $36.33–$36.39, opened at $36.36.
- Volume was 960.89K shares, 0.7x its 50-day average of 1.34M.
- Price is +36.8% vs its 50-day average ($26.57) and +49.9% vs its 200-day average ($24.24).
- 52-week range $18.80–$36.67; today's close sits at 98% of that range, 0.9% below the 52-week high.
Oct 15, 2026 — PCRX ends flat (-0.2%) to $36.33
- Closed at $36.33, -0.19% vs the prior close of $36.40. Day range $36.31–$36.67, opened at $36.39.
- Volume was 2.06M shares, 1.6x its 50-day average of 1.33M.
- Price is +37.8% vs its 50-day average ($26.36) and +50.2% vs its 200-day average ($24.19).
- 52-week range $18.80–$36.67; today's close sits at 98% of that range, 0.9% below the 52-week high.
Oct 14, 2026 — PCRX ends flat (+0.2%) to $36.40, a 52-week high
- Closed at $36.40, +0.25% vs the prior close of $36.31. Day range $36.31–$36.48, opened at $36.33.
- Volume was 2.33M shares, 1.8x its 50-day average of 1.31M.
- Price is +39.3% vs its 50-day average ($26.13) and +50.8% vs its 200-day average ($24.14).
- 52-week range $18.80–$36.48; today's close sits at 100% of that range, 0.2% below the 52-week high.
Oct 13, 2026 — PCRX ends flat (-0.1%) to $36.31
- Closed at $36.31, -0.11% vs the prior close of $36.35. Day range $36.30–$36.35, opened at $36.35.
- Volume was 2.22M shares, 1.7x its 50-day average of 1.29M.
- Price is +39.9% vs its 50-day average ($25.95) and +50.8% vs its 200-day average ($24.09).
- 52-week range $18.80–$36.46; today's close sits at 99% of that range, 0.4% below the 52-week high.
Oct 12, 2026 — PCRX ends flat (+0.1%) to $36.35
- Closed at $36.35, +0.11% vs the prior close of $36.31. Day range $36.32–$36.35, opened at $36.34.
- Volume was 2.01M shares, 1.6x its 50-day average of 1.26M.
- Price is +41.1% vs its 50-day average ($25.76) and +51.2% vs its 200-day average ($24.03).
- 52-week range $18.80–$36.46; today's close sits at 99% of that range, 0.3% below the 52-week high.
Oct 9, 2026 — PCRX ends flat (-0.2%) to $36.31 on 4.0x normal volume
- Closed at $36.31, -0.22% vs the prior close of $36.39. Day range $36.31–$36.36, opened at $36.33.
- Volume was 4.69M shares, 4.0x its 50-day average of 1.17M — unusually heavy trading.
- Price is +42.0% vs its 50-day average ($25.56) and +51.4% vs its 200-day average ($23.98).
- 52-week range $18.80–$36.46; today's close sits at 99% of that range, 0.4% below the 52-week high.
Oct 8, 2026 — PCRX jumps 44.4% to $36.39, a 52-week high on 47.6x normal volume
- Closed at $36.39, +44.40% vs the prior close of $25.20. Day range $36.27–$36.46, opened at $36.33.
- Volume was 28.90M shares, 47.6x its 50-day average of 606.66K — unusually heavy trading.
- Price is +43.4% vs its 50-day average ($25.38) and +52.1% vs its 200-day average ($23.93).
- 52-week range $18.80–$36.46; today's close sits at 100% of that range, 0.2% below the 52-week high.
- SEC filings that day: 8-K.
Oct 7, 2026 — PCRX rises 1.8% to $25.20
- Closed at $25.20, +1.78% vs the prior close of $24.76. Day range $24.99–$26.00, opened at $25.05.
- Volume was 802.70K shares, 1.3x its 50-day average of 599.93K.
- Price is +0.1% vs its 50-day average ($25.18) and +5.5% vs its 200-day average ($23.88).
- 52-week range $18.80–$27.66; today's close sits at 72% of that range, 8.9% below the 52-week high.
Oct 6, 2026 — PCRX dips 1.2% to $24.76
- Closed at $24.76, -1.16% vs the prior close of $25.05. Day range $24.56–$25.25, opened at $25.13.
- Volume was 493.10K shares, 0.8x its 50-day average of 601.14K.
- Price is -1.8% vs its 50-day average ($25.21) and +3.7% vs its 200-day average ($23.88).
- 52-week range $18.80–$27.66; today's close sits at 67% of that range, 10.5% below the 52-week high.
Oct 5, 2026 — PCRX dips 0.6% to $25.05
- Closed at $25.05, -0.63% vs the prior close of $25.21. Day range $24.83–$25.71, opened at $25.37.
- Volume was 560.20K shares, 0.9x its 50-day average of 598.44K.
- Price is -0.8% vs its 50-day average ($25.24) and +4.8% vs its 200-day average ($23.89).
- 52-week range $18.80–$27.66; today's close sits at 71% of that range, 9.4% below the 52-week high.
Oct 2, 2026 — PCRX rises 0.8% to $25.21
- Closed at $25.21, +0.80% vs the prior close of $25.01. Day range $24.66–$25.66, opened at $25.04.
- Volume was 469.80K shares, 0.8x its 50-day average of 605.03K.
- Price is -0.2% vs its 50-day average ($25.26) and +5.5% vs its 200-day average ($23.90).
- 52-week range $18.80–$27.66; today's close sits at 72% of that range, 8.9% below the 52-week high.
PCRX latest news & SEC filings
Every SEC filing by or about PCRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Riker Lauren converted options/RSUs into 6,000 shares at $32.35 (≈$194.10K) on Oct 8, 2026; now holds 68,284
- Riker Lauren sold 6,000 shares at $36.32 (≈$217.92K) on Oct 8, 2026; now holds 62,284
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 8, 2026 · Form SC TO-C — SC TO-C filing
SC TO-C filing
Oct 8, 2026 · Form SC14D9C — SC14D9C filing
SC14D9C filing
Oct 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 8, 2026 · Form SC TO-C — SC TO-C filing
SC TO-C filing
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Slonin Jonathan sold 3,040 shares at $23.23 (≈$70.62K) on Aug 17, 2026
- Slonin Jonathan sold 3,040 shares at $23.23 (≈$70.62K) on Aug 17, 2026
- Slonin Jonathan sold 3,040 shares at $23.23 (≈$70.62K) on Aug 17, 2026
- Slonin Jonathan sold 3,040 shares at $23.23 (≈$70.62K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $192.40M (prior year $181.10M) (+6.2% vs Jun 30, 2025)
- Net income: $4.65M (prior year -$4.85M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.12 (prior year -$0.11) (swung to profit vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade PCRX
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 26, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.24% (largest 44.4%). That is a volatile stock.
- Liquidity: about 2.51M shares (≈$91.10M) trade per day on average.
- 52-week position: $36.34 vs a range of $18.80–$36.67 (98% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jonathan Slonin sold 3,040 shares on Aug 17, 2026.
- Latest filings: 8-K Oct 8, 2026; 10-Q Aug 4, 2026; 8-K Aug 4, 2026.
- Share count: 39.86M shares outstanding (Aug 3, 2026), -11.3% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PCRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 36.36 | 36.39 | 36.33 | 36.34 | 960.89K |
| Oct 15, 2026 | 36.39 | 36.67 | 36.31 | 36.33 | 2.06M |
| Oct 14, 2026 | 36.33 | 36.48 | 36.31 | 36.40 | 2.33M |
| Oct 13, 2026 | 36.35 | 36.35 | 36.30 | 36.31 | 2.22M |
| Oct 12, 2026 | 36.34 | 36.35 | 36.32 | 36.35 | 2.01M |
| Oct 9, 2026 | 36.33 | 36.36 | 36.31 | 36.31 | 4.69M |
| Oct 8, 2026 | 36.33 | 36.46 | 36.27 | 36.39 | 28.90M |
| Oct 7, 2026 | 25.05 | 26.00 | 24.99 | 25.20 | 802.70K |
| Oct 6, 2026 | 25.13 | 25.25 | 24.56 | 24.76 | 493.10K |
| Oct 5, 2026 | 25.37 | 25.71 | 24.83 | 25.05 | 560.20K |
| Oct 2, 2026 | 25.04 | 25.66 | 24.66 | 25.21 | 469.80K |
| Oct 1, 2026 | 25.05 | 25.38 | 24.93 | 25.01 | 510.60K |
| Sep 30, 2026 | 25.59 | 25.77 | 24.91 | 25.05 | 628.50K |
| Sep 29, 2026 | 25.30 | 25.67 | 25.13 | 25.65 | 643.60K |
| Sep 28, 2026 | 25.15 | 25.76 | 24.79 | 25.39 | 478.80K |
| Sep 25, 2026 | 25.50 | 25.66 | 25.00 | 25.12 | 444.20K |
| Sep 24, 2026 | 24.58 | 25.60 | 24.50 | 25.56 | 725.10K |
| Sep 23, 2026 | 25.00 | 25.21 | 24.51 | 24.63 | 450.70K |
| Sep 22, 2026 | 24.36 | 24.97 | 24.20 | 24.70 | 380.50K |
| Sep 21, 2026 | 24.79 | 24.99 | 23.98 | 24.11 | 375.50K |
About Pacira BioSciences
Pacira BioSciences (PCRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BRISBANE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1396814.
PCRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Marcelo Bigal | Director | Jun 12, 2026 |
| Laura Brege | Director | Jun 12, 2026 |
| Christopher Christie | Director | Jun 12, 2026 |
| Mark Froimson | Director | Jun 12, 2026 |
| Samit Hirawat | Director | Jun 12, 2026 |
| Mark A. Kronenfeld | Director | Mar 19, 2026 |
| Frank D. Lee | Chief Executive Officer | Feb 13, 2026 |
| Thomas G Wiggans | Director | Jun 12, 2026 |
| Michael J. Yang | Director | Jun 12, 2026 |
| Alethia Young | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Shawn Cross | Chief Financial Officer | Apr 24, 2026 |
| Frank D. Lee | Chief Executive Officer | Feb 13, 2026 |
| Lauren Riker | Senior Vice President, Finance | Jun 12, 2026 |
| Jonathan Slonin | Chief Medical Officer | Aug 18, 2026 |
| Brendan Teehan | Chief Commercial Officer | Feb 13, 2026 |
| Kristen Williams | Chief Administrative Officer | Jun 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Jonathan Slonin | Sale | 3,040 | $23.23 |
| Aug 17, 2026 | Jonathan Slonin | Sale | 3,040 | $23.23 |
| Aug 17, 2026 | Jonathan Slonin | Sale | 3,040 | $23.23 |
| Aug 17, 2026 | Jonathan Slonin | Sale | 3,040 | $23.23 |
| Jun 11, 2026 | Lauren Riker | Sale | 6,115 | $23.50 |
| Jun 11, 2026 | Lauren Riker | Sale | 6,115 | $23.50 |
| Jun 11, 2026 | Lauren Riker | Sale | 6,115 | $23.50 |
| Jun 11, 2026 | Lauren Riker | Sale | 6,115 | $23.50 |
| Jun 4, 2026 | Kristen Williams | Sale | 10,259 | $22.27 |
| Jun 4, 2026 | Kristen Williams | Sale | 10,259 | $22.27 |
| Jun 4, 2026 | Kristen Williams | Sale | 10,259 | $22.27 |
| Jun 4, 2026 | Kristen Williams | Sale | 10,259 | $22.27 |
| Apr 23, 2026 | Shawn Cross | Sale | 12,941 | $25.16 |
| Apr 23, 2026 | Shawn Cross | Sale | 12,941 | $25.16 |
| Apr 23, 2026 | Shawn Cross | Sale | 12,941 | $25.16 |
PCRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $726.41M | $7.03M | 0.16 | $151.99M |
| Dec 31, 2024 | $700.97M | $-99.56M | -2.15 | $189.39M |
| Dec 31, 2023 | $674.98M | $41.95M | 0.89 | $154.65M |
| Dec 31, 2022 | $666.82M | $15.91M | 0.34 | $145.27M |
| Dec 31, 2021 | $541.53M | $41.98M | 0.92 | $125.72M |
Latest balance sheet: total assets $1.24B, total liabilities $572.00M, cash $205.88M (as of Jun 30, 2026).
PCRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $27.62 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $25.49 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $22.59 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $26.02 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $21.10 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $22.54 |
| May 8, 2025 | 8-K Item 2.02 (results) | $24.91 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $25.38 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $20.64 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $17.67 |
| Jul 30, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PCRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.